PerkinElmer's epigenetic detection reagents portfolio is specifically validated for drug discovery and life sciences research.
The screening assays for epigenetics are built upon the company's proprietary
homogeneous assay platforms, Lance Ultra detection assays for peptide
substrates and AlphaLISA detection assays for both peptide or full-length
proteins. Both platforms are no-wash, non-radioactive , antibody-based
technologies, that offer a unique combination of specificity, sensitivity,
dynamic range, and throughput. All are validated for mark specificity,
providing the sensitivity to work with low substrate and enzyme
concentrations, generating robust and reproducible assay signals.
PerkinElmer’s epigenetic and post-translational screening tools now cover nine
different histone marks as well as p53, with more than 15 validated enzyme
assays to help researchers discover novel drug compounds directed against
several epigenetic enzymes, such as histone methyltransferases (HMTs),
demethylases (HDMs), acetyltransferases (HATs), and deacetylases (HDACs).
PerkinElmer is a global technology leader driving growth and innovation in
Health Sciences and Photonics markets to improve the quality of life.
Combining operational excellence and technology expertise with an intimate
understanding of its customers' needs, PerkinElmer provides products and
services to customers who require innovation, precision and reliability. The
company is a leading provider of scientific instruments, consumables and
services to the pharmaceutical, biomedical, environmental testing and
general industrial markets.